Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), another highly expressed target gene in the ASCL1 subtype of SCLC, can be targeted by labetuzumab govitecan [80]. The gene discussed is ASCL1; the disease is small cell lung carcinoma.